Mira Pharmaceuticals Michelle Yanez Steps Down As CFO Of Mira Pharmaceuticals; Alan Weichselbaum Appointed As CFO Effective May 15, 2025
MIRAMay 21, 2025
Read more →Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Gives Stock $17.75 Price Valuation
MIRAMay 15, 2025
Read more →EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million
MIRAMira Pharmaceuticals to acquire SKNY in a stock-based deal valuing both firms near $30 million each, backed by third-party pipeline valuation reports.
May 8, 2025
Read more →EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga Co's Board Of Directors Approve SKNY Pharmaceuticals Acquisition Following Independent Valuation, Says Combined Enterprise Value Exceeding $60M
MIRAMay 8, 2025
Read more →EXCLUSIVE: MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study
MIRAKetamir-2 from MIRA Pharmaceuticals showed no brain toxicity in rats, meeting FDA study requirements and advancing its clinical development program.
May 6, 2025
Read more →EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga 'Preclinical data supports the advancement of oral Ketamir-2 as a safe, next-generation alternative to ketamine, with ongoing momentum in Phase I clinical trial enrollment'
MIRAMay 6, 2025
Read more →EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga Co. Reports No Brain Toxicity In FDA-Required Study Of Ketamir-2, Says Confirming Absence Of Ketamine-Linked Neurotoxicity
MIRAMay 6, 2025
Read more →MIRA Pharmaceuticals Highlights In Vitro Drug Release Data For Topical Ketamir-2
MIRAApril 23, 2025
Read more →MIRA Pharmaceuticals Announced A Key Development Milestone For Its Novel Topical Formulation Of Ketamir-2 Demonstrated Successful, Dose-proportional Drug Release In A Validated Laboratory Study-8K
MIRAApril 23, 2025
Read more →Is Mira Pharmaceuticals Gaining or Losing Market Support?
MIRAApril 17, 2025
Read more →EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study
MIRAMIRA's Ketamir-2 shows promise in treating diabetic neuropathy, with a Phase 2a trial expected by late 2025 and human data in early 2026.
April 16, 2025
Read more →EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga 'Ketamir-2 Demonstrates Strong Efficacy in Diabetic Neuropathy Model, with Some Subjects Achieving Complete Symptom Reversal'
MIRAApril 16, 2025
Read more →EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga Co. Announces Results For Ketamir-2 In Diabetic Neuropathy Animal Model, Says Reinforcing Confidence Ahead Of Phase I Completion
MIRAApril 16, 2025
Read more →EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug
MIRAMIRA Pharmaceuticals signs letter of intent to acquire SKNY Pharmaceuticals, adding SKNY-1, a preclinical drug for weight loss and smoking cessation, to its portfolio.
March 24, 2025
Read more →EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga 'Strategic acquisition expands MIRA's pipeline with SKNY-1, a next-generation oral therapeutic targeting the two leading causes of preventable death—obesity and smoking'
MIRAMarch 24, 2025
Read more →EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga Co. Signs Binding LOI To Acquire SKNY Pharmaceuticals, Says Securing $5M Capital Infusion To Advance Weight Loss And Smoking Cessation Drug Development
MIRAMarch 24, 2025
Read more →Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Gives Stock $17.75 Price Valuation
MIRAMarch 13, 2025
Read more →EXCLUSIVE: MIRA Pharmaceuticals Expands Pipeline, Enhances Value Proposition With Development Of Topical Formulation For Lead Pain Treatment Candidate
MIRAMIRA Pharmaceuticals unveils Ketamir-2 topical for neuropathic pain, complementing its oral version. Clinical and preclinical studies are advancing this year.
March 13, 2025
Read more →EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga 'This advancement expands the Company's pain management portfolio beyond its ongoing Ketamir-2 oral treatment for neuropathic pain'
MIRAMarch 13, 2025
Read more →EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga Co. Expands Ketamir-2 Development With Topical Treatment For Localized Neuropathic And Inflammatory Pain
MIRAMarch 13, 2025
Read more →EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain
MIRAMIRA Pharmaceuticals gains approval for a Phase 1 trial of Ketamir-2 in Israel, aiming to complete by Q4 2025 before moving to Phase 2a in neuropathic pain.
March 4, 2025
Read more →EXCLUSIVE: Mira Pharmaceuticals Tells Benzinga Co. Announces Approval And Initiation Of Phase I Clinical Trial For Ketamin-2 In Neuropathic Pain
MIRAMarch 4, 2025
Read more →EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment
MIRAMIRA Pharmaceuticals submits an IND for Ketamir-2, aiming to treat neuropathic pain with 100% pain reversal shown in preclinical studies.
December 19, 2024
Read more →Mira Pharmaceuticals Announced The Selection Of The Centre For Human Drug Research In Leiden, The Netherlands, As The Site For Its Phase I/IIa Clinical Trial Of Ketamir-2, A Novel Oral Ketamine Analog
MIRANovember 20, 2024
Read more →Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Says Co Is Creating A THC Analog That Has The Same Benefits As THC Without The Negative Side Effects. We Value MIRA At $16.50 Using Discontinued Cash Flow Analysts And A 20% Discount Rate.
MIRAMay 22, 2024
Read more →MIRA Pharmaceuticals Discusses With Memorial Sloan Kettering To Collaborate On A Preclinical Cancer Pain Model Utilizing The Co's Novel Oral Ketamine Analog
MIRAMay 21, 2024
Read more →Mira Pharmaceuticals Advances Preclinical Studies Using Ketamir-2 Towards Clinical Development
MIRAMay 20, 2024
Read more →